Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to improve breast cancer surgery precision

NCT ID NCT07185568

Symptom relief Sponsor: Istituto Oncologico Veneto IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three techniques—ultrasound, wire, and magnetic seed—to help surgeons remove non-palpable breast tumors more accurately during breast-conserving surgery. About 1,300 adult women with early-stage breast cancer will be randomly assigned to one of the three methods. The goal is to see which technique results in fewer positive margins (cancer cells at the edge of removed tissue) and reduces the need for repeat surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,302 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with non-palpable breast cancer candidate for breast-conserving surgery; * Female patients; * Patients aged ≥ 18 years; * Patients with histologic diagnosis of cT1-T2 invasive BC or ductal carcinoma in situ; * Patients amenable for BCS after neoadjuvant chemotherapy; * Patients who are able to give informed consent. Exclusion Criteria: * Pregnancy or lactation; * Patients with locally advanced disease or metastatic disease; * Patients with palpable breast carcinoma; * Patients candidate for mastectomy; * Patients who are unable to give informed consent * Patients candidate for mastectomy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma in situ breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast conserving surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AOU Policlinico di Modena

    Modena, Italy

  • ASL2 Abruzzo, Ospedale "Gaetano Bernabeo", Ortona

    Ortona, Italy

  • Azienda Ospedaliera San Giovanni Addolorata

    Roma, RM, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, RM, Italy

  • Istituto Oncologico Veneto IRCCS

    Padova, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.